<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265952</url>
  </required_header>
  <id_info>
    <org_study_id>R1500-CL-1331</org_study_id>
    <nct_id>NCT02265952</nct_id>
  </id_info>
  <brief_title>Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)</brief_title>
  <official_title>An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm study to assess the reduction of low-density lipoprotein
      cholesterol (LDL-C) by REGN1500 in patients with homozygous familial hypercholesterolemia
      (HoFH).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 4, 2015</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 21, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in low-density lipoprotein cholesterol (LDL-C) from baseline (week 0) to week 4.</measure>
    <time_frame>Week 0 to week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in LDL-C from week 2 to week 4</measure>
    <time_frame>Week 2 to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in LDL-C from week 2 to week 4</measure>
    <time_frame>Week 2 to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in LDL-C over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in LDL-C over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in LDL-C from baseline over time in the open label extension (OLE) period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in LDL-C from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in LDL-C from baseline (week 0) to week 4</measure>
    <time_frame>Week 0 to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Apo B, non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (total-C), and lipoprotein (Lp) (a) over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in Apo B, non-HDL-C, total-C, and Lp (a) over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apo B, non-HDL-C, total-C, and Lp (a) from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Apo B, non-HDL-C, total-C, and Lp (a) from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve a reduction in LDL-C of ≥15% from baseline in the main study</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve a reduction in LDL-C of ≥15% from baseline in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥30% reduction in LDL-C from baseline in the main study</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ≥30% reduction in LDL-C from baseline in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in HDL-C, triglycerides, and Apo A-1 over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HDL-C, triglycerides, and Apo A-1 over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in HDL-C, triglycerides, and Apo A-1 from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HDL-C, triglycerides, and Apo A-1 from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Apo CIII over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in Apo CIII over time in the main study period</measure>
    <time_frame>Week 0 to week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apo CIII from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Apo CIII from baseline over time in the OLE period</measure>
    <time_frame>Week 26 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs) reported from the first dose of study drug to the end of study or the last visit in subjects treated with REGN1500</measure>
    <time_frame>Week 2 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of REGN1500 over time</measure>
    <time_frame>Week 0 to week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and titer of anti-REGN1500 antibodies over time</measure>
    <time_frame>Week 0 to week 214</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Open-Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label REGN1500</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1500</intervention_name>
    <arm_group_label>Open-Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women ≥18 years of age at the time of the screening visit

          2. Diagnosis of homozygous familial hypercholesterolemia (HoFH)

          3. Willing to consistently maintain usual diet for the duration of the study

        Exclusion Criteria:

          1. Background medical lipid modifying therapy that has not been stable for at least 4
             weeks (6 weeks for fibrates) prior to the screening visit

          2. Having undergone lipid apheresis within 4 weeks prior to the screening visit

          3. Use of another investigational drug or therapy within 30 days or at least 5 half-lives
             (whichever is longer) prior to the screening visit

          4. Previous participation in any clinical trial of REGN1500

        Note: The information listed above is not intended to contain all considerations relevant
        to a patient's potential participation in this clinical trial therefore not all inclusion/
        exclusion criteria are listed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, Chyu KY, Sasiela WJ, Chan KC, Brisson D, Khoury E, Banerjee P, Gusarova V, Gromada J, Stahl N, Yancopoulos GD, Hovingh GK. ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. N Engl J Med. 2017 Jul 20;377(3):296-297. doi: 10.1056/NEJMc1705994.</citation>
    <PMID>28723334</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <disposition_first_submitted>October 30, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>October 30, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 6, 2017</disposition_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

